Baxter International Inc ( (BAX) ) has released its Q1 earnings. Here is a breakdown of the information Baxter International Inc presented to its investors.
Baxter International Inc. is a leading global medical technology company that specializes in providing a wide range of healthcare products and services, including diagnostic, critical care, nutrition, hospital, and surgical products. The company operates in over 100 countries, focusing on innovations that save and sustain lives.
In its first-quarter 2025 earnings report, Baxter International Inc. announced a 5% increase in sales from continuing operations, totaling $2.63 billion, surpassing its previous guidance. The company’s adjusted diluted earnings per share (EPS) from continuing operations also exceeded expectations, reaching $0.55.
Key financial highlights include an 11% increase in U.S. sales and a 3% operational increase in international sales. The Medical Products & Therapies segment reported a 6% operational growth, while the Healthcare Systems & Technologies segment saw a 6% increase in both reported and operational sales. The Pharmaceuticals segment experienced a 3% operational growth, driven by specialty injectables.
Baxter’s management expressed confidence in the company’s trajectory despite global economic uncertainties, raising the lower end of its full-year 2025 adjusted EPS guidance. The company anticipates a 7% to 8% sales growth on a reported basis for the full year.
Looking forward, Baxter International Inc. remains committed to its transformation journey, focusing on execution, innovation, and profitable growth to address the pressing needs of its customers and stakeholders.